Neurología

A continuación, se enumeran los ensayos clínicos actuales.

Filtra esta lista de estudios por sede, estatus, etc.

1. Natural History Study Protocol in PMM2-CDG (CDG-Ia)

   Rochester, Minn.

   Clinical and Basic Investigations into Phosphomannomutase deficiency (PMM2-CDG) This is a natural history (observational) protocol designed to collect clinical and biological information in patients with PMM2-CDG (CDG-Ia). Data from this natural history study will be used to determine a set of clinical and biological parameters that will be used for primary and secondary endpoints in a later clinical trial with a new chemical entity, Lipo-M1P.

2. HEALEY ALS Platform Trial

   Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to evaluate the safety and effectiveness of investigational products for the treatment of ALS.

3. The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech

   Rochester, Minn.

   The purpose of this study is to identify and distinguish two different types of Progressive Apraxia of Speech through clinical imaging and testing.

4. A Study to Evaluate Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Patients

   Rochester, Minn.

   The purpose of this study is to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims:

5. A Study to Evaluate Newly-diagnosed Idiopathic Generalized Epilepsy

   Rochester, Minn.

   The purpose of this study is to identify clinical characteristics and biomarkers predictive of disease outcome, progression, and treatment response in participants with idiopathic generalized epilepsy (IGE).

6. Posterior Fossa Decompression with or without Duraplasty for Chiari Type I Malformation with Syringomyelia

   Rochester, Minn.

   The purpose of this study is to determine whether a posterior fossa decompression or a posterior fossa decompression with duraplasty results in better patient outcomes with fewer complications and improved quality of life in those who have Chiari malformation type I and syringomyelia.

7. Ado-trastuzumab emtansine (T-DM1)-Induced Peripheral Neuropathy in HER2-positive Breast Cancer Patients

   Rochester, Minn.

   The purpose of this study is to prospectively evaluate the patient-reported outcomes data of T-DM1 induced peripheral neuropathy like prior research focused on paclitaxel-, paclitaxel/CBDCA-, oxaliplatin-, and cisplatin-induced peripheral neuropathy, to better understand the similarities and differences of chemotherapy-induced peripheral neuropathy (CIPN) symptoms caused by different agents, their pathogenesis, and impacts.

8. Phase 2 Study of TAK-341 for Multiple System Atrophy

   Rochester, Minn.

   The purpose of this study is to evaluate the effectiveness of TAK-341 versus placebo, as measured by the change from baseline to Week 52 on l Unified Multiple System Atrophy Rating Scale (UMSARS) Part I, minus the sexual function item, with collapse of the normal and mild ratings on each item.

9. A Study of Mood Symptoms in Epilepsy Patients

   Rochester, Minn.

   The purpose of this study is to track neuropsychiatric symptoms in patients with epilepsy.

10. Submandibular Gland Needle Core Biopsy and Skin Punch Biopsy as Tissue Biomarkers for the Diagnosis and Monitoring of Disease Progression of Parkinson’s Disease and REM Sleep Behavior Disorder

    Scottsdale/Phoenix, Ariz.

    Determine 1) the magnitude of SMG and skin a-syn density change over time, 2) the

    improvement in adequate tissue acquisition doing bilateral SMG biopsies, 3) any laterality differences between

    SMG gland a-syn density, 4) correlate a-syn density and changes in density between SMG and skin biopsies

    Specific Aim 1. Determine, with bilateral submandibular gland (SMG) biopsies in 30 clinically

    diagnosed subjects with Parkinson’s disease (PD) and 20 clinically probable REM sleep behavior

    disorder (RBD) subjects whether bilateral biopsies improve the rate of acquisition of adequate

    glandular tissue, whether alpha-synuclein (a-syn) SMG pathology correlates with clinical severity

    and/or disease duration, and whether there is a left-right difference in the density of a-syn pathology.

    Specific Aim 2. Determine, with a second SMG biopsy in previously biopsied PD and RBD subjects,

    whether a-syn pathology density increases, decreases, or remains the same after a 1.5-2 year time

    interval and whether there is a correlation between a-syn SMG pathology and clinical and/or disease

    progression.

    Specific Aim 3. Determine whether a-syn pathology density in skin punch biopsies correlates

    with clinical measures and increases, decreases, or remains the same after a 1.5-2 year time

    interval, and whether the density and changes over time correlate with those found in SMG

    biopsies.